UA42061C2 - Фармацевтична композиція для перорального введення, що містить інгібітори протонного насоса - Google Patents

Фармацевтична композиція для перорального введення, що містить інгібітори протонного насоса

Info

Publication number
UA42061C2
UA42061C2 UA97115326A UA97115326A UA42061C2 UA 42061 C2 UA42061 C2 UA 42061C2 UA 97115326 A UA97115326 A UA 97115326A UA 97115326 A UA97115326 A UA 97115326A UA 42061 C2 UA42061 C2 UA 42061C2
Authority
UA
Ukraine
Prior art keywords
proton pump
pharmaceutical composition
oral pharmaceutical
composition
composition containing
Prior art date
Application number
UA97115326A
Other languages
English (en)
Russian (ru)
Inventor
Кошик Дж. Дейв
Джеймс Б. Уілльямс
Джеймс Б. Уильямс
Original Assignee
Мерк Енд Ко, Інк
Мерк энд Ко, Инк
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Мерк Енд Ко, Інк, Мерк энд Ко, Инк filed Critical Мерк Енд Ко, Інк
Publication of UA42061C2 publication Critical patent/UA42061C2/uk

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
    • A61K47/08—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite containing oxygen, e.g. ethers, acetals, ketones, quinones, aldehydes, peroxides
    • A61K47/14—Esters of carboxylic acids, e.g. fatty acid monoglycerides, medium-chain triglycerides, parabens or PEG fatty acid esters
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
    • A61K31/415—1,2-Diazoles
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
    • A61K31/4164—1,3-Diazoles
    • A61K31/4184—1,3-Diazoles condensed with carbocyclic rings, e.g. benzimidazoles
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
    • A61K31/4427—Non condensed pyridines; Hydrogenated derivatives thereof containing further heterocyclic ring systems
    • A61K31/4439—Non condensed pyridines; Hydrogenated derivatives thereof containing further heterocyclic ring systems containing a five-membered ring with nitrogen as a ring hetero atom, e.g. omeprazole
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
    • A61K47/08—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite containing oxygen, e.g. ethers, acetals, ketones, quinones, aldehydes, peroxides
    • A61K47/12—Carboxylic acids; Salts or anhydrides thereof
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/44—Oils, fats or waxes according to two or more groups of A61K47/02-A61K47/42; Natural or modified natural oils, fats or waxes, e.g. castor oil, polyethoxylated castor oil, montan wax, lignite, shellac, rosin, beeswax or lanolin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0053—Mouth and digestive tract, i.e. intraoral and peroral administration
    • A61K9/006—Oral mucosa, e.g. mucoadhesive forms, sublingual droplets; Buccal patches or films; Buccal sprays
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/04—Drugs for disorders of the alimentary tract or the digestive system for ulcers, gastritis or reflux esophagitis, e.g. antacids, inhibitors of acid secretion, mucosal protectants

Abstract

У даному винаході пропонується стабільна пероральна фармацевтична композиція у формі пасти, що містить у якості активного інгредієнту інгібiтор протонного насосу. Композиція придатна для доставки лабільних у кислоті лікарських засобів тваринам, зокрема коням, та людям, що мають складнощі під час ковтання твердих лікарських форм, таких як таблетки та капсули. Більш конкретно, дана композиція містить: один або декілька інгібіторів протонного насосу, гідрофобний олійний носій, підлуговуючий агент та загусник.
UA97115326A 1995-04-04 1996-03-29 Фармацевтична композиція для перорального введення, що містить інгібітори протонного насоса UA42061C2 (uk)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US08/416,275 US5708017A (en) 1995-04-04 1995-04-04 Stable, ready-to-use pharmaceutical paste composition containing proton pump inhibitors
PCT/US1996/004355 WO1996031213A1 (en) 1995-04-04 1996-03-29 Pharmaceutical composition containing proton pump inhibitors

Publications (1)

Publication Number Publication Date
UA42061C2 true UA42061C2 (uk) 2001-10-15

Family

ID=23649308

Family Applications (1)

Application Number Title Priority Date Filing Date
UA97115326A UA42061C2 (uk) 1995-04-04 1996-03-29 Фармацевтична композиція для перорального введення, що містить інгібітори протонного насоса

Country Status (30)

Country Link
US (1) US5708017A (uk)
EP (1) EP0819004B1 (uk)
JP (1) JP4603631B2 (uk)
KR (1) KR100419105B1 (uk)
CN (1) CN1080119C (uk)
AT (1) ATE438380T1 (uk)
AU (1) AU703755B2 (uk)
BR (1) BR9604803A (uk)
CA (1) CA2217515C (uk)
CY (1) CY2613B2 (uk)
CZ (1) CZ287297B6 (uk)
DE (1) DE69637985D1 (uk)
DK (1) DK0819004T3 (uk)
EA (1) EA000087B1 (uk)
EE (1) EE03473B1 (uk)
ES (1) ES2329098T3 (uk)
HK (1) HK1004658A1 (uk)
HU (1) HU227864B1 (uk)
IS (1) IS2706B (uk)
MX (1) MX9707694A (uk)
NO (1) NO312994B1 (uk)
NZ (1) NZ305708A (uk)
PL (1) PL183144B1 (uk)
PT (1) PT819004E (uk)
SI (1) SI0819004T1 (uk)
SK (1) SK282872B6 (uk)
TR (1) TR199701117T1 (uk)
UA (1) UA42061C2 (uk)
WO (1) WO1996031213A1 (uk)
ZA (1) ZA962657B (uk)

Families Citing this family (59)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
DK173431B1 (da) * 1998-03-20 2000-10-23 Gea Farmaceutisk Fabrik As Farmaceutisk formulering omfattende en 2-[[(2-pyridinyl)methyl]sulfinyl]benzimidazol med anti-ulcusaktivitet samt fremgangs
EP1004305B1 (en) * 1998-04-20 2011-09-28 Eisai R&D Management Co., Ltd. Stabilized compositions containing benzimidazole-type compounds
US6093734A (en) * 1998-08-10 2000-07-25 Partnership Of Michael E. Garst, George Sachs, And Jai Moo Shin Prodrugs of proton pump inhibitors
ID28273A (id) 1998-08-10 2001-05-10 Partnership Of Michael E Garst Prodrug inhibitor pompa proton
CA2346646A1 (en) * 1998-10-06 2000-04-13 Mars Uk Limited Animal stereotypy
ES2216870T3 (es) * 1999-02-23 2004-11-01 MERCK & CO., INC. Composicion farmaceutica que contiene inhibidores de la bomba de protones.
FR2793688B1 (fr) 1999-05-21 2003-06-13 Ethypharm Lab Prod Ethiques Microgranules gastroproteges, procede d'obtention et preparations pharmaceutiques
JP4081273B2 (ja) 1999-10-20 2008-04-23 エーザイ・アール・アンド・ディー・マネジメント株式会社 ベンズイミダゾール系化合物安定化方法
GB2358136A (en) * 2000-01-15 2001-07-18 Univ Montfort A medicament for the treatment of equine oral stereotypies using a pH regulator
US6787342B2 (en) 2000-02-16 2004-09-07 Merial Limited Paste formulations
NZ522450A (en) * 2000-05-30 2004-07-30 Merial Ltd Methods for prevention of ulcers
US6544556B1 (en) 2000-09-11 2003-04-08 Andrx Corporation Pharmaceutical formulations containing a non-steroidal antiinflammatory drug and a proton pump inhibitor
WO2002026210A2 (en) * 2000-09-29 2002-04-04 Geneva Pharmaceuticals Inc. Proton pump inhibitor formulation
WO2002032427A1 (en) * 2000-10-20 2002-04-25 Galephar M/F Stable oral formulation containing benzimidazole derivative
RU2271810C2 (ru) * 2000-10-27 2006-03-20 Лео Фарма А/С Композиции местного применения, содержащие, по меньшей мере, один витамин d или один аналог витамина d и, по меньшей мере, один кортикостероид
SI1341524T1 (sl) * 2000-12-07 2012-02-29 Nycomed Gmbh Farmacevtski pripravek v obliki paste, ki obsega kislinsko labilno učinkovino
WO2002045692A1 (en) * 2000-12-07 2002-06-13 Altana Pharma Ag Pharmaceutical preparation in the form of a suspension comprising an acid-labile active ingredient
US20050019390A1 (en) * 2001-10-26 2005-01-27 John Kohnke Dosage system and dosage vehicle therefor
AUPS244002A0 (en) * 2002-05-20 2002-06-13 John Kohnke Products Pty Ltd Agent delivery system
US20030228363A1 (en) * 2002-06-07 2003-12-11 Patel Mahendra R. Stabilized pharmaceutical compositons containing benzimidazole compounds
CA2490142A1 (en) * 2002-07-03 2004-01-15 Abbott Laboratories Liquid dosage forms of proton pump inhibitors
RU2292342C2 (ru) * 2002-07-19 2007-01-27 Уинстон Фармасьютикалс ЛЛС. Производные бензимидазола и их применение в качестве пролекарств ингибиторов протонного насоса
GB2394895A (en) * 2002-11-06 2004-05-12 Cipla Ltd Proton pump inhibitor composition in paste form
JP2006516562A (ja) * 2003-01-24 2006-07-06 ステート オブ イスラエル、ミニストリー オブ アグリカルチャー 抗酸化活性を増強するための相乗的な組成物及び方法
EP2112920B1 (en) 2003-06-26 2018-07-25 Intellipharmaceutics Corp. Proton pump-inhibitor-containing capsules which comprise subunits differently structured for a delayed release of the active ingredient
WO2005000269A1 (en) * 2003-06-26 2005-01-06 Cipla Limited Pharmaceutical formulations comprising a proton pump inhibitor
US20050075371A1 (en) * 2003-10-03 2005-04-07 Allergan, Inc. Methods and compositions for the oral administration of prodrugs of proton pump inhibitors
US20060241037A1 (en) * 2003-10-03 2006-10-26 Allergan Inc. Compositions comprising trefoil factor family peptides and/or mucoadhesives and proton pump ihhibitor prodrugs
JP2007523163A (ja) * 2004-02-18 2007-08-16 アラーガン、インコーポレイテッド プロトンポンプインヒビターのプロドラッグの投与のための方法および組成物
BRPI0507837A (pt) * 2004-02-18 2007-07-10 Allergan Inc métodos e composições para a administração intravenosa de compostos relacionados a inibidores de bomba de prótons
WO2005097083A2 (en) * 2004-03-30 2005-10-20 Dermatrends,Inc. Transdermal administration of proton pump inhibitors
WO2005117870A2 (en) * 2004-04-16 2005-12-15 Santarus, Inc. Combination of proton pump inhibitor, buffering agent, and prokinetic agent
US8394409B2 (en) * 2004-07-01 2013-03-12 Intellipharmaceutics Corp. Controlled extended drug release technology
US10624858B2 (en) 2004-08-23 2020-04-21 Intellipharmaceutics Corp Controlled release composition using transition coating, and method of preparing same
WO2006026829A1 (en) * 2004-09-09 2006-03-16 Metelli Pty Ltd Stable paste composition of enteric coated acid labile active agent and use thereof
US10064828B1 (en) 2005-12-23 2018-09-04 Intellipharmaceutics Corp. Pulsed extended-pulsed and extended-pulsed pulsed drug delivery systems
RS54543B1 (en) * 2006-01-27 2016-06-30 Yale University Fast acting gastric acid secretion inhibitor
CA2648280C (en) * 2006-04-03 2014-03-11 Isa Odidi Controlled release delivery device comprising an organosol coat
US10960077B2 (en) * 2006-05-12 2021-03-30 Intellipharmaceutics Corp. Abuse and alcohol resistant drug composition
CA2654402A1 (en) * 2006-06-01 2007-12-06 Adel Penhasi Multiple unit pharmaceutical formulation
US20100317689A1 (en) * 2006-09-19 2010-12-16 Garst Michael E Prodrugs of proton pump inhibitors including the 1h-imidazo[4,5-b] pyridine moiety
AU2007317561A1 (en) 2006-10-27 2008-05-15 The Curators Of The University Of Missouri Compositions comprising at least one acid labile proton pump inhibiting agents, optionally other pharmaceutically active agents and methods of using same
US20080194307A1 (en) * 2007-02-13 2008-08-14 Jeff Sanger Sports-based game of chance
WO2008121887A1 (en) 2007-03-30 2008-10-09 Enterprises International, Inc. Strapping track assembly and method of using the same
JP2011512416A (ja) 2008-02-20 2011-04-21 ザ・キュレイターズ・オブ・ザ・ユニバーシティー・オブ・ミズーリ オメプラゾール及びランソプラゾールの組合せと緩衝剤を含んでなる組成物とそれを使用する方法
EP2262536A4 (en) * 2008-03-26 2013-07-03 Taro Pharmaceuticals North America Inc STABILIZING LIPID COMPOSITIONS FOR ORAL PHARMACEUTICAL AGENTS
BRPI0918652B1 (pt) 2008-09-17 2021-10-19 Chiasma, Inc. Composição farmacêutica compreendendo um meio hidrofóbico e uma forma sólida que compreende polipeptídeo e sal de ácido graxo de cadeia média, processo de produção da mesma e forma de dosagem oral
DE102009018133A1 (de) * 2009-04-15 2010-11-11 Agon Pharma Gmbh Pharmazeutische Zusammensetzung zur Behandlung von dermatologischen Autoimmunerkrankungen
GB201306720D0 (en) * 2013-04-12 2013-05-29 Special Products Ltd Formulation
EP3253401A4 (en) 2015-02-03 2018-11-21 Chiasma Inc. Method of treating diseases
EP3288556A4 (en) 2015-04-29 2018-09-19 Dexcel Pharma Technologies Ltd. Orally disintegrating compositions
US10076494B2 (en) 2016-06-16 2018-09-18 Dexcel Pharma Technologies Ltd. Stable orally disintegrating pharmaceutical compositions
US10137111B2 (en) 2016-08-11 2018-11-27 Adamis Pharmaceuticals Corporation Drug compositions comprising an anti-parasitic and proton pump inhibitor
EP3299017A1 (en) * 2016-09-23 2018-03-28 The Boots Company PLC Formulation
CN107397719A (zh) * 2017-08-16 2017-11-28 洛阳市兽药厂 一种畜禽用奥美拉唑可溶性粉剂及其制备工艺
EP3720844A4 (en) 2017-12-08 2021-08-11 Adamis Pharmaceuticals Corporation MEDICINAL COMPOSITIONS
GB201804621D0 (en) * 2018-03-22 2018-05-09 Bcm Specials Ltd Formulation
US11141457B1 (en) 2020-12-28 2021-10-12 Amryt Endo, Inc. Oral octreotide therapy and contraceptive methods
GB202116644D0 (en) 2021-11-18 2022-01-05 Innovate Pharmaceuticals Ltd Liquid composition

Family Cites Families (10)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
SE7804231L (sv) * 1978-04-14 1979-10-15 Haessle Ab Magsyrasekretionsmedel
IL75400A (en) * 1984-06-16 1988-10-31 Byk Gulden Lomberg Chem Fab Dialkoxypyridine methyl(sulfinyl or sulfonyl)benzimidazoles,processes for the preparation thereof and pharmaceutical compositions containing the same
JPS6150978A (ja) * 1984-08-16 1986-03-13 Takeda Chem Ind Ltd ピリジン誘導体およびその製造法
AU4640985A (en) * 1984-08-31 1986-03-06 Nippon Chemiphar Co. Ltd. Benzimidazole derivatives
AU3683889A (en) * 1988-06-30 1990-01-23 Upjohn Company, The Transdermal antisecretory agents for gastrointestinal disease
JP2694361B2 (ja) * 1989-02-09 1997-12-24 アストラ アクチエボラグ 抗菌剤
KR930000861B1 (ko) * 1990-02-27 1993-02-08 한미약품공업 주식회사 오메프라졸 직장투여 조성물
SE9301489D0 (sv) * 1993-04-30 1993-04-30 Ab Astra Veterinary composition
KR0142815B1 (ko) * 1994-12-02 1998-07-15 정도언 신규한 5-피롤릴-6-할로게노-2피리딜메틸설피닐벤즈이미다졸 유도체
GB2290965A (en) * 1994-07-11 1996-01-17 Therapicon Srl Multiple layer capsules for drugs

Also Published As

Publication number Publication date
ES2329098T3 (es) 2009-11-20
MX9707694A (es) 1997-12-31
HU227864B1 (en) 2012-05-29
EA199700294A1 (ru) 1998-02-26
EP0819004B1 (en) 2009-08-05
JP4603631B2 (ja) 2010-12-22
HK1004658A1 (en) 1998-12-04
CZ287297B6 (en) 2000-10-11
EP0819004A4 (en) 2006-01-18
SK282872B6 (sk) 2003-01-09
KR100419105B1 (ko) 2004-05-31
DK0819004T3 (da) 2009-11-30
CY2613B2 (en) 2011-04-06
PL322619A1 (en) 1998-02-02
ATE438380T1 (de) 2009-08-15
AU5379796A (en) 1996-10-23
DE69637985D1 (de) 2009-09-17
CZ313597A3 (cs) 1998-04-15
EE03473B1 (et) 2001-08-15
IS2706B (is) 2011-01-15
EE9700244A (et) 1998-04-15
HUP9801626A3 (en) 2000-06-28
CA2217515C (en) 2005-03-15
CN1185107A (zh) 1998-06-17
HUP9801626A2 (hu) 1999-02-01
BR9604803A (pt) 1998-06-09
US5708017A (en) 1998-01-13
PL183144B1 (pl) 2002-05-31
NZ305708A (en) 1999-11-29
JPH11503160A (ja) 1999-03-23
KR19980703576A (ko) 1998-11-05
PT819004E (pt) 2009-10-12
NO974589L (no) 1997-12-03
WO1996031213A1 (en) 1996-10-10
NO312994B1 (no) 2002-07-29
AU703755B2 (en) 1999-04-01
CN1080119C (zh) 2002-03-06
EA000087B1 (ru) 1998-06-25
IS4576A (is) 1997-10-02
CA2217515A1 (en) 1996-10-10
SI0819004T1 (sl) 2009-12-31
SK135097A3 (en) 1998-06-03
TR199701117T1 (xx) 1998-02-21
EP0819004A1 (en) 1998-01-21
ZA962657B (en) 1996-10-09
NO974589D0 (no) 1997-10-03

Similar Documents

Publication Publication Date Title
UA42061C2 (uk) Фармацевтична композиція для перорального введення, що містить інгібітори протонного насоса
FI955124A0 (fi) Protonipumppuinhibiittorin sisältävä eläinlääkeseos
ATE345782T1 (de) Dosierungsformen enthaltend geschmacksmaskierten wirkstoffen
RU95109905A (ru) Композиции в жидком, полутвердом, твердом, гелеобразном или пастообразном виде и способ лечения заболеваний полости рта
AR022930A2 (es) MICROCAPSULAS, DE TIPO RESERVORIO, QUE CONTIENEN POR LO MENOS UN PRINCIPIO ACTIVO MEDICAMENTOSO Y/O NUTRITIVO (PA) CON EXCLUSION DEL ACIDO ACETILSALICILICO (ASA), DESTINADAS A LA ADMINISTRACION POR VIA ORAL, SU UTILIZACIoN Y FORMA FARMACEUTICA QUE COMPRENDE A DICHAS MICROCAPSULAS.
DE69431533D1 (de) Dosierungsform zur verabreichung von flüssige arzneimittel formulierung
BG100933A (en) Polymer coated tablets comprising amoxycilin and clavulanate
BG105754A (en) Pharmaceutical composition containing proton pump inhibitors
DK0969843T3 (da) Antitussive formuleringer indeholdende theobromin
TR199701294T1 (xx) Amoksisilin ve klavulanik asitten olu�an terkip.
PH27446A (en) Compound with gastric acid inhibitory effect
BR9912533A (pt) Composição farmacêutica tendo sabor melhorado
MY100780A (en) Azumolene dosage form.
ATE85218T1 (de) Oral anzuwendende arzneiform zur einmal taeglichen behandlung der hypertonie mit diltiazemhydrochlorid.
MY102368A (en) Solid sustained-release composition
ECSP961835A (es) Nuevo procedimiento
JO1881B1 (en) Formula II for multi unit disc calibration